VAXXAIR TRIAL: In-depth Immunological Analysis of Airway Immunity following Nasal Live Attenuated and Intramuscular Influenza Vaccine A randomized controlled trial
The VAXXAIR trial is exploring how different types of flu vaccines protect our breathing passages. While many adults receive a standard flu injection into the arm, children often receive a nasal spray. This study compares the standard flu jab with the nasal spray vaccine to understand how each triggers immune defences in the nose, throat, and blood. Participants will be randomly assigned to receive either the injection, the nasal spray, or a dummy nasal spray (placebo). Researchers will take small samples, such as blood tests and nasal swabs, before vaccination and at several points up to three months afterwards. By examining how antibodies and specialised white blood cells respond, scientists hope to learn how best to stop flu viruses where they first enter the body. This information could lead to better vaccines for everyone.
At a glance
What is this study about?
Influenza, commonly known as the flu, is a contagious chest and throat infection caused by flu viruses. Every year, flu vaccines protect millions of people from severe illness. Most adults receive their annual flu vaccine as an injection in the arm. However, there is also a nasal spray version, which is routinely offered to school-aged children in the UK. Because the flu virus enters our bodies through our nose and mouth, researchers want to know whether a nasal vaccine provides stronger 'frontline' protection in the airways compared to a traditional jab.
The VAXXAIR study aims to look closely at how the immune system responds inside the nose and lungs after vaccination. When your body meets a vaccine, it creates antibodies (protective proteins) and activates specialised white blood cells (called T-cells and B-cells) to fight off future infections. By looking at these cells and antibodies in both the blood and respiratory fluids, doctors can map out the exact immune shield that each vaccine type produces.
Taking part in this study helps researchers understand the fine details of airway immunity. This knowledge is vital for improving seasonal flu vaccines and preparing better defences against potential new respiratory viruses. The findings could shape how vaccines are given in the NHS in future years.
Key takeaways
- Compares standard flu injections with nasal spray vaccines in adults.
- Investigates how immune cells and antibodies protect the nose and airways.
- Open to adults aged 18 and over.
- Involves clinic visits over approximately three months with blood and nasal samples.
- Participation is voluntary, and you can withdraw at any time.
Who may be eligible?
This trial is open to adults aged 18 and older of any sex. Because it is looking at general immune responses, doctors are looking for volunteers who are willing to have their immune system monitored closely over a few months.
While the basic criteria welcome any adult, you will have a health check with the study team first. They will need to make sure that receiving a flu vaccine or nasal spray is safe for you, and that you do not have any specific allergies or underlying health conditions that might interfere with the results.
If you have already had your annual flu jab this season, or if you take medications that alter your immune system, you might not be able to take part. The research team will discuss your medical history with you in detail before you decide to sign up.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I am happy to receive a flu vaccine or nasal spray.
- I am available to attend clinic visits over a three-month period.
- I am willing to provide blood samples and gentle nose swabs.
- I have not yet received my flu vaccine for the current season.
What does participation involve?
If you take part, you will be placed into a study group by chance (randomly). You will receive either the standard flu injection in your arm, the nasal spray vaccine, or a harmless dummy nasal spray (placebo).
The study lasts around three to four months in total. You will attend several clinic visits: one about two weeks before vaccination, the vaccination visit itself, and follow-up visits around one week, four weeks, and three months later. During these visits, the team will collect blood samples and take gentle swabs or fluid samples from your nose to measure your antibodies and immune cells. You may also be asked to keep a brief diary of any mild symptoms or side effects you notice.
Potential risks and benefits
Locations (1)
- —UnverifiedDenmark
Common questions
What is the main purpose of this study?
The study aims to see whether a nasal spray or an injection creates better immune protection inside the nose and airways against the flu.
Is the nasal spray safe for adults?
Yes. The nasal spray vaccine is well-studied and approved for use. The study team will check your medical history to make sure it is safe for you.
Can I choose whether I get the jab or the spray?
No. A computer will randomly choose which vaccine you receive so that the study results remain fair and unbiased.
Will taking part give me the flu?
No. The vaccines cannot give you the flu. The injected vaccine contains no live virus, and the nasal spray uses a weakened form that cannot cause a chest infection.
What happens if I change my mind?
You can leave the study at any time. Your decision will not change the standard of healthcare you normally receive.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.